Clinical Trial

A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase I study of HRS-7172 to evaluate safety, tolerability and pharmacokinetics in participants with advanced solid tumors harboring RAS mutations or amplifications.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-20.
Status change: Not Yet Recruiting → Recruiting 2025-11-13
Trial Details
NCT Number NCT07142980
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Enrollment 120 participants
Start Date 2025-09-12
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-11-17